News

VectivBio

VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

OCTOBER 13, 2022

Immunovant

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

OCTOBER 4, 2022

Allakos

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

SEPTEMBER 19, 2022

Abivax

Abivax announces successful oversubscribed EUR 49.2M cross-over financing

SEPTEMBER 2, 2022

Upstream Bio

Upstream Bio Launches with $200M Series A

JUNE 2, 2022

Plexium

Plexium Announces $102M Financing

FEBRUARY 23, 2022

Eikon Therapeutics

Eikon Therapeutics Announces $517.8 Million Series B Raise

JANUARY 6, 2022

Arbor Biotechnologies

Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing

NOVEMBER 9, 2021

Entrada Therapeutics

Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering

OCTOBER 28, 2021

ShouTi

ShouTi Secures $100 Million Series B Financing

OCTOBER 20, 2021

Obsidian

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

SEPTEMBER 9, 2021

Artios

Artios Announces $153 Million Series C Financing

JULY 27, 2021

RayzeBio

RayzeBio Secures $108 Million Series C Financing

JUNE 15, 2021

Synthekine

Synthekine Announces $107.5 Million Oversubscribed Series B Financing

JUNE 10, 2021

Affinia Therapeutics

Affinia Therapeutics Closes $110 Million Series B Financing

MAY 3, 2021

TCG X

TCG X Raises Inaugural $824 Million Fund to Advance Disruptive Medicines

APRIL 20, 2021

Entrada Therapeutics

Entrada Therapeutics Announces Closing of $116 Million Series B Financing

MARCH 31, 2021

Aktis Oncology

Aktis Oncology Announces $72 Million Series A Financing to Advance Breakthrough Radiopharmaceuticals

MARCH 18, 2021